In a population of over 90 million people, with over 24,000 new cases of breast cancer each year and rising [37], and with the financial burden of cancer care frequently falling on the shoulders of the patient [38], estimating Ki-67 by IHC would be a far more affordable way to determine prognosis and predict response to therapy than the use of expensive multi-gene assays. Here, MKI67 is linked to breast cancer.